Neurotropin, which is a unique non-protein extract isolated from the inflamed dermis of rabbits inoculated with vaccinia virus, has been demonstrated to have beneficial effects in immune-suppressed or autoimmune animals. To further understand the mechanism of action of Neurotropin, we examined its effects on the thymic microenvironment renal pathology and levels of anti-DNA antibodies in (NZB x NZW)F1 mice, one of the principal murine lupus models. We have previously reported that (NZB x NZW)F1 mice or other murine lupus models have distinctive abnormalities in their thymic microenvironment. in this study we have taken advantage of a well-characterized panel of monoclonal antibodies that recognize cortical, medullary, and non-epithelial elements within the thymic architecture. Neurotropin significantly improved several thymic cortical and medullary abnormalities including irregular shape, diffused networks and/or reduced staining in 6-month-old (NZB x NZW)F1 mice by treatment with 40 Neurotropin unit/kg body weight by daily i.p. injection for 14 days with data similar to age-matched BALB/c mice. Neurotropin also improved the abnormalities of extracellular matrix which expressed abnormal shapes and was increased markedly in the thymus of 6-month-old (NZB x NZW)F1 mice. The architecture of the extracellular matrix in Neurotropin-treated (NZB x NZW)F1 mice expressed a similar shape as age-matched control BALB/c mice. Moreover Neurotropin significantly reduced proteinuria in (NZB x NZW)F1 mice compared to proteinuria in saline-treated (NZB x NZW)F1 mice which showed high levels. The results suggest that Neurotropin has beneficial effects on architectural abnormalities of thymus and nephritic syndromes, and may be important in the treatment of human patients with systemic lupus erythematosus (SLE).
|Original language||English (US)|
|Number of pages||10|
|Journal||International Journal of Immunotherapy|
|State||Published - 1997|
ASJC Scopus subject areas
- Immunology and Allergy